-
Hansa Biopharma provides business update including certain key financials
LUND, Sweden, Jan. 9, 2022 /PRNewswire/ — Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in Central Eastern Europe and Israel First patients enrolled into the pivotal U.S. ConfIdeS study; Agreement established with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease Platform strategy: Hansa to explore desensitization treatment in allogeneic hematopoietic stem cell transplantation Year-end cash position of SEK 889 million; Hansa financed into 2023, as previously guided Hansa Biopharma AB, “Hansa”, (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare
-
ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
ERYTECH Provides Business and Financial Update for the Third Quarter of 2021 Conference call and webcast on Tuesday, November 16, 2021at 8:30am EST / 2:30pm CET Progress towards seeking approval of eryaspase for the treatment of ALL patients who experienced hypersensitivity to pegylated asparaginase; Fast Track designation granted; submission of BLA intended around year-end Phase 3 trial in second–line pancreatic cancer did not meet its primary endpoint Process to review strategic options and partnering alternatives launched Cambridge, MA (U.S.) and Lyon (France), November 15, 2021 – ERYTECH Pharma (Nasdaq
-
Euroclear Business and Financial update
BRUSSELS, Oct. 29, 2021 /CNW/ — Financial highlights Q3 YTD 2021 operating income up 9% year-on-year to EUR 1156 million as strong Business Income growth offset lower Banking and Other Income Operating costs increased by 6% to EUR 676 million, including exceptional costs related to the MFEX acquisition Net profit increased by 11% to EUR 347 million EPS increased 11% to EUR 110.3 per share Euroclear logo (PRNewsfoto/Euroclear) Key Operating Metrics remain strong Assets under custody reached EUR 36.1 trillion an increase of 15% year on year Record number of netted transactions settled in the Euroclear group of
-
NOXXON Reports H1 2021 Financial Results and Provides Business Update
Positive results from two cohorts of Phase 1/2 clinical trial with NOX-A12 in brain cancer; full readout expected in Q1 2022 Appointment of Scientific Advisory Board with top US and EU pancreatic cancer experts Appointment of 3 new Supervisory Board members with remarkable experience Strengthening the Company’s balance sheet by raising a total of €9.3 million ensuring financial visibility into June 2022 BERLIN, October 22, 2021–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces its financial results and business highlights
-
Home improvement big box stores update COVID mask policies
Home Depot & Lowe’s have adjusted their polices based on the increase in COVID cases nationwide LINCOLN, Neb. (KLKN) – Two big names in home improvement have updated their mask policies nationwide. Both Home Depot and Lowe’s updated their policies effective Monday in light of growing COVID cases. LOWE’S UPDATE 8/2: “The health and safety of our associates and customers continue to be our highest priority. Because of the increased cases of COVID-19 and the rapid spread of the delta variant, effective August 2, Lowe’s associates are required to wear masks indoors at all U.S. locations and while working in
The Go-To Source For Marvelous Servise
